Cullinan Therapeutics, Inc.

CGEM

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$21.68

+$0.30 · +1.40%

Aug 21, 4:00 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

47/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Expensive

Momentum

Gaining

Sentiment

Bullish

Risk resilience

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Nadim Ahmed
Listed since: Jan 8, 2021
Employees: 109

Market position

Day range

Current $21.68

$21.42$22.12

52-week range

Current $21.68

$5.68$22.54

Open: $21.52
Previous close: $21.38
Volume: 758.22K; 0.81× average
Average volume: 938.03K; Average daily volume
Market cap: 1.33B USD
Beta: -0.01; Market reference 1
50-day average: $17.7644; +22.04% above average
200-day average: $13.9031; +55.94% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 525.52M USD
P/E (TTM): -6.43×
P/B (TTM): 4.14×
P/S (TTM): 0×
EV / EBITDA: -2.39×
Earnings yield: -35.98%
Free cash flow yield: -28.76%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -53.80%
Return on assets: -49.04%
Return on invested capital: -58.74%

Financial health

Debt / equity: 0.01×
Current ratio: 10.25×
Altman Z-score: 15.46
Piotroski F-score: 1 of 9

Financial statements

Income trends

Operating income

−241.65M USD-22.71%

Net income

−219.88M USD-31.36%

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	—	—	—	—	18.94M USD
Cost of goods sold	—	306K USD	—	—	—
Gross profit	—	−306K USD	—	—	18.94M USD
Research and development	187.4M USD	142.9M USD	148.16M USD	91.95M USD	57.75M USD
Selling, general, and administrative	54.25M USD	53.71M USD	42.49M USD	40.19M USD	29.15M USD
Operating expenses	241.65M USD	196.61M USD	191.09M USD	−144.65M USD	86.9M USD
Interest income	22.21M USD	29.66M USD	21.63M USD	6.61M USD	477K USD
Depreciation and amortization	311K USD	306K USD	310K USD	93K USD	53K USD
Operating income	−241.65M USD	−196.92M USD	−191.09M USD	144.65M USD	−67.95M USD
Net income	−219.88M USD	−167.38M USD	−153.16M USD	111.21M USD	−65.57M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS: -3.72; FY2025
Latest fiscal-year revenue: 0 USD; FY2025
Next fiscal-year EPS consensus: -3.17; FY2026 · 8 analysts
Next fiscal-year revenue consensus: 12.62M USD; FY2026 · 7 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$32.20

48.52% upside

Past 12 months12-month forecastHigh $39.00Average $32.20Low $27.00

Recent analyst actions

7 institutions

Morgan StanleymaintainOverweightAug 18, 2025

UBSmaintainBuyMay 12, 2025

StifelmaintainBuyFeb 28, 2025

JonesTradingmaintainBuyApr 17, 2024

CGEM news

businesswire.comAug 19, 2026

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLC…

Read source

benzinga.comAug 13, 2026

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

Taiho Oncology Inc., Taiho Pharmaceutical Co. Ltd., and Cullinan Therapeutics Inc. (NASDAQ:CGEM) on Thursday shared data from their global REZILIENT3 Phase 3 trial of zipalertinib in certain lung cancer patients.

Read source

businesswire.comAug 12, 2026

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer…

Read source

globenewswire.comAug 6, 2026

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027

Read source

globenewswire.comJul 28, 2026

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T…

Read source

seekingalpha.comJun 11, 2026

Cullinan Therapeutics: Heading Toward Paydirt

Cullinan Therapeutics remains a compelling buy as zipalertinib approaches a key FDA decision for EGFR exon 20 insertion NSCLC. Zipalertinib demonstrates promising efficacy, including CNS activity and responses…

Read source